Number of shares and votes in Calliditas Therapeutics
Calliditas Therapeutics AB (publ) has reported changes in its share structure due to the exercise of warrants under its long-term incentive programs. As of July 31, 2024, the company's total outstanding shares have increased to 59,941,465 ordinary shares, with an equal number of votes. The share capital has risen by SEK 14,455.12, from SEK 2,383,203.48 to SEK 2,397,658.60. These changes result from the exercise of warrants under the ESOP 2020 and LTIP 2021 programs. This information is disclosed in compliance with the Swedish Financial Instruments Trading Act.
Calliditas Therapeutics AB (publ) ha riportato modifiche nella sua struttura azionaria a seguito dell'esercizio di warrant nell'ambito dei suoi programmi di incentivi a lungo termine. Al 31 luglio 2024, il numero totale di azioni in circolazione è aumentato a 59.941.465 azioni ordinarie, con un numero equivalente di voti. Il capitale sociale è aumentato di SEK 14.455,12, passando da SEK 2.383.203,48 a SEK 2.397.658,60. Queste modifiche derivano dall'esercizio di warrant nell'ambito dei programmi ESOP 2020 e LTIP 2021. Queste informazioni sono divulgate in conformità con la Legge svedese sugli strumenti finanziari.
Calliditas Therapeutics AB (publ) ha reportado cambios en su estructura de acciones debido al ejercicio de warrants bajo sus programas de incentivos a largo plazo. A partir del 31 de julio de 2024, el número total de acciones en circulación ha aumentado a 59.941.465 acciones ordinarias, con una cantidad equivalente de votos. El capital social ha aumentado en SEK 14.455,12, pasando de SEK 2.383.203,48 a SEK 2.397.658,60. Estos cambios son el resultado del ejercicio de warrants bajo los programas ESOP 2020 y LTIP 2021. Esta información se divulga de acuerdo con la Ley de Comercio de Instrumentos Financieros de Suecia.
Calliditas Therapeutics AB (publ)는 장기 인센티브 프로그램에 따른 워런트 행사로 인해 주식 구조의 변화를 보고했습니다. 2024년 7월 31일 현재, 발행된 총 주식 수는 59,941,465 보통주로 증가했으며, 이에 상응하는 의결권 수 또한 동일합니다. 발행 자본은 SEK 14,455.12 증가하여 SEK 2,383,203.48에서 SEK 2,397,658.60로 올랐습니다. 이러한 변화는 ESOP 2020 및 LTIP 2021 프로그램의 워런트 행사의 결과입니다. 이 정보는 스웨덴 금융상품 거래법에 따라 공개됩니다.
Calliditas Therapeutics AB (publ) a rapporté des modifications de sa structure d'actions en raison de l'exercice de bons de souscription dans le cadre de ses programmes d'incitation à long terme. Au 31 juillet 2024, le nombre total d'actions en circulation a augmenté à 59.941.465 actions ordinaires, avec un nombre équivalent de droits de vote. Le capital social a augmenté de SEK 14.455,12, passant de SEK 2.383.203,48 à SEK 2.397.658,60. Ces changements résultent de l'exercice de bons de souscription dans le cadre des programmes ESOP 2020 et LTIP 2021. Ces informations sont divulguées conformément à la loi suédoise sur le commerce des instruments financiers.
Calliditas Therapeutics AB (publ) hat Änderungen in seiner Aktienstruktur aufgrund der Ausübung von Warrants im Rahmen seiner langfristigen Anreizprogramme gemeldet. Am 31. Juli 2024 hat sich die Gesamtzahl der ausgegebenen Aktien auf 59.941.465 Stammaktien erhöht, mit einer entsprechend hohen Anzahl von Stimmrechten. Das Eigenkapital ist um SEK 14.455,12 gestiegen, von SEK 2.383.203,48 auf SEK 2.397.658,60. Diese Änderungen sind das Ergebnis der Ausübung von Warrants im Rahmen der Programme ESOP 2020 und LTIP 2021. Diese Informationen werden gemäß dem schwedischen Handelsgesetz für Finanzinstrumente offengelegt.
- Increase in total outstanding shares indicates potential capital inflow
- Exercise of warrants suggests confidence in company's future prospects
- None.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2 p.m. CEST on July 31, 2024.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company based in
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Number of shares and votes July 2024 (Eng) |
View original content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-302211062.html
SOURCE Calliditas Therapeutics
FAQ
How many outstanding shares does Calliditas Therapeutics (CALT) have as of July 31, 2024?
What caused the change in Calliditas Therapeutics' (CALT) share count in July 2024?
How much did Calliditas Therapeutics' (CALT) share capital increase in July 2024?
What is the total number of votes in Calliditas Therapeutics (CALT) as of July 31, 2024?
